New Alzheimer’s drug’s approval could come in July
Cambridge- based Biogen and Japan- based Eisai announced Sunday evening that federal regulators would make a decision whether to grant their drug full approval by July 6, a verdict that all-important Medicare coverage hinges on. Eisai, which is overseeing interactions with regulators, is confident that Leqembi will meet the bar for full approval.
This article is available to Insider Pro subscribers only.Sign in or register to be an Insider Pro and access ALL LOCKED articles.
Key Hawaii Senate vote today on measure aimed at physician retention
Michigan pushes to address insulin costs
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News